Document is current
Any future updates will be listed below
-
Authors
Mosele, Fernanda https://orcid.org/0000-0001-7841-2900
Deluche, Elise https://orcid.org/0000-0001-8474-3116
Lusque, Amelie
Le Bescond, Loïc
Filleron, Thomas
Pradat, Yoann https://orcid.org/0000-0002-4647-5779
Ducoulombier, Agnes
Pistilli, Barbara https://orcid.org/0000-0002-9184-7199
Bachelot, Thomas https://orcid.org/0000-0002-0866-9484
Viret, Frederic
Levy, Christelle
Signolle, Nicolas
Alfaro, Alexia
Tran, Diep T. N. https://orcid.org/0000-0002-3982-4221
Garberis, Ingrid Judith https://orcid.org/0000-0002-0501-8520
Talbot, Hugues
Christodoulidis, Stergios https://orcid.org/0000-0002-8773-1070
Vakalopoulou, Maria
Droin, Nathalie https://orcid.org/0000-0002-6099-5324
Stourm, Aurelie
Kobayashi, Maki https://orcid.org/0000-0001-5920-5906
Kakegawa, Tomoya
Lacroix, Ludovic
Saulnier, Patrick
Job, Bastien
Deloger, Marc https://orcid.org/0000-0002-6352-101X
Jimenez, Marta https://orcid.org/0000-0002-4233-8478
Mahier, Celine https://orcid.org/0000-0001-8368-3174
Baris, Vianney https://orcid.org/0009-0001-8162-5920
Laplante, Pierre
Kannouche, Patricia https://orcid.org/0000-0002-6050-3457
Marty, Virginie https://orcid.org/0000-0002-9122-9438
Lacroix-Triki, Magali https://orcid.org/0000-0002-6641-8536
Diéras, Veronique https://orcid.org/0000-0001-8094-4738
André, Fabrice https://orcid.org/0000-0001-5795-8357
-
Funding
Funding for this research was provided by:
Daiichi Sankyo Company
UNICANCER PRISM
Daiichi-Sankyo
UNICANCER PRISM
- License Information
-
More Information
Article History
Received: 20 September 2022
Accepted: 28 June 2023
First Online: 24 July 2023
Competing interests
: F.M. received consultant fees from Novartis and Pegascy. E.D. received personal fees and non-financial support from Novartis, Pfizer, AstraZeneca, Daiichi Sankyo, GlaxoSmithKline, Eli Lilly and Merck Sharp & Dohme. T.F. received consultant fees outside the submitted work and compensation to the institution from Cellectis, Roche and Eli Lilly. B.P. received fees as advisor/consultant from Pierre Fabre (self), Daiichi Sankyo (self), Merck Sharp & Dohme (institution), Seattle Genetics (institution), Eli Lilly (institution) and Novartis (institution); funding to institution for research support from Daiichi Sankyo and AstraZeneca; and travel expenses from AstraZeneca, Pfizer and Gilead. T.B. reports receiving grants and personal fees from Daiichi Sankyo, AstraZeneca, Pfizer and Seattle Genetics and personal fees from Novartis and Roche outside the submitted work. M.K. and T.K. are employees of Daiichi Sankyo RD Novare. M.L.T. received consultant fees as speaker and consultant from AstraZeneca and Daiichi Sankyo. V.D. received travel expenses from Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, Daiichi Sankyo, Seagen and Gilead; honoraria as consultant/advisor from Roche, Genentech, Novartis, Eli Lilly, Pfizer, AstraZeneca, AbbVie, Merck Sharp & Dohme, Daiichi Sankyo, Seagen, Gilead, Eisai and Pierre Fabre Oncologie; and honoraria for symposia from Roche, Novartis, Pfizer, Eli Lilly, Astra Zeneca, Daiichi Sankyo, Seagen and Gilead. F.A. received research funding and served as speaker/advisor (compensated to the hospital) from Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis and Eli Lilly. The following authors have no disclosures: A.L., L.L.B., Y.P., A.D., F.V., C.L., N.S., A.A., D.T.N.T., I.J.G., H.T., S.C., M.V., N.D., A.S., L.L., P.S., J.B., M.D., M.J., C.M., V.B., P.L., P.K. and V.M.
